# Bloom Science

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/bloom-science

- Industry: Biotechnology
- Headquarters: San Diego, US
- Website: www.bloomscience.com
- Total disclosed funding: $12M
- Latest round: Series A (Dec 9, 2021)
- Investors on record: 4

## About

Bloom Science, Inc. is a biotechnology company focused on developing innovative live biotherapeutic products that target metabolic and neurological disorders through advanced synthetic biology techniques.Founded in 2018 and headquartered in San Diego, US, Bloom Science specializes in live biotherapeutics. The company has made strides in securing funding with a successful Series A round in December 2021, raising USD 12.000 mn. The founders, Christopher Reyes, Elaine Hsiao, Raphael Valdivia, and Tony Colasin, have combined expertise in biotechnology and healthcare innovation, with Christopher Reyes serving as the CEO.Bloom Science primarily offers BL-001, a live biotherapeutic product designed to replicate the clinical efficacy of the ketogenic diet. This innovative product targets metabolic and neurological disorders by leveraging gut commensal microbes and synthetic biology through their proprietary IrisRx™ discovery platform. The end use cases for BL-001 include treatment for obesity and Dravet syndrome, with the product demonstrating a proof of mechanism and a favorable safety profile. Bloom Science aims to serve a diverse client base comprising healthcare providers, research institutions, and potentially patients suffering from complex conditions such as ALS and other metabolic health issues. Their products are primarily marketed in North America and Europe, focusing on regions where the demand for advanced therapies targeting metabolic and neurological health is growing.Bloom Science generates revenue through partnerships and collaborations with various healthcare organizations and research institutions. The business model involves direct sales to healthcare providers or through strategic alliances that facilitate the distribution of BL-001 and other future therapeutics. Transactions typically revolve around licensing agreements or collaborative agreements that support drug development and commercialization efforts. The flagship product, BL-001, is central to these transactions, with pricing structures determined by agreements established with partners, including pricing for clinical trials and potential future launches in healthcare markets. The company's revenue model positions it to capitalize on the increasing demand for innovative treatments that address unmet medical needs in metabolic and neurological health.In December 2021, Bloom Science, Inc. raised USD 12.000 mn in Series A funding co-led by new investors Leaps by Bayer and SUNU Ventures, with participation from Apollo Health Ventures and Joyance Partners. The company will use the funding to advance its pipeline including its lead program BL-001, which is being developed for orphan, drug-resistant epilepsies. Bloom Science is also targeting expansion into new markets across North America and Europe to further address the growing demand for their innovative therapies.

## Funding rounds

- Series A, Dec 9, 2021, $12M — SUNU Ventures, Apollo Health Ventures, Joyance Partners, Leaps by Bayer

## Investors

- SUNU Ventures (https://capitalatlas.ai/funds/sunu-ventures) — Series A
- Apollo Health Ventures (https://capitalatlas.ai/funds/apollo-health-ventures) — Series A
- Joyance Partners (https://capitalatlas.ai/funds/joyance-partners) — Series A
- Leaps by Bayer (https://capitalatlas.ai/funds/leaps-by-bayer) — Series A